Drug profile · INN
vilobelimab
GOHIBIC
vilobelimab (GOHIBIC) is a complement c5 inhibitor.
EMA: approved Antineoplastic and immunomodulating agents (L04) L04AJ10
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — vilobelimab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
vilobelimab (GOHIBIC) is a complement c5 inhibitor.
Key facts
INN vilobelimab
Brand GOHIBIC
Mechanism Complement C5 inhibitor
Target Complement C5
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AJ10
Mechanism of action
Complement C5 inhibitor
Primary target: Complement C5
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is vilobelimab?
vilobelimab (GOHIBIC) is a complement c5 inhibitor.
What is the brand name for vilobelimab?
GOHIBIC is a marketed brand name for vilobelimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.